Effects on Cardiovascular Risk Scores and Vascular Age After Aerobic Exercise and Nutritional Intervention in Sedentary and Overweight/Obese Adults with Primary Hypertension: The EXERDIET-HTA Randomized Trial Study by Gorostegi-Anduaga, Ilargi et al.
This is a post-peer-review, pre-copyedit version of an article published in High Blood Pressure & 
Cardiovascular Prevention. The final authenticated version is available online at: 
https://doi.org/10.1007/s40292-018-0281-0  
 
 
Effects on cardiovascular risk scores and vascular age after aerobic exercise and nutritional 1 
intervention in sedentary and overweight/obese adults with primary hypertension: The EXERDIET-2 
HTA randomized trial study 3 
Running title: Cardiovascular risk assessment 4 
Authors of the manuscript: 5 
Ilargi Gorostegi-Anduaga,1 Sara Maldonado-Martín,1 Aitor MartinezAguirre-Betolaza,1 Pablo Corres,1 6 
Estíbaliz Romaratezabala,1 Anna C Whittaker,2 Silvia Francisco-Terreros,3 Javier Pérez-Asenjo4 7 
1 Laboratory of Performance Analysis in Sport. Department of Physical Education and Sport. Faculty 8 
of Education and Sport-Physical Activity and Sport Science Section. University of the Basque Country 9 
(UPV/EHU). Vitoria-Gasteiz. Araba/Álava. Basque Country, Spain 10 
2 School of Sport, Exercise and Rehabilitation Sciences. University of Birmingham. Edgbaston, 11 
Birmingham, UK 12 
3 Clinical Trials Unit. Health and Quality of Life Area. TECNALIA. Vitoria-Gasteiz. Araba/Álava. Basque 13 
Country, Spain  14 
4 Cardiology Unit. Igualatorio Médico Quirúrgico (IMQ-Amárica). Vitoria-Gasteiz. Araba/Álava. 15 
Basque Country, Spain  16 
Corresponding author: Sara Maldonado-Martín. Department of Physical Education and Sport. 17 
Faculty of Education and Sport. University of the Basque Country (UPV/EHU). Portal de Lasarte, 71. 18 
01007 Vitoria-Gasteiz (Araba/Alava)-Basque Country, Spain. Phone: +34 945013534. Fax:+34 19 
945013501. E-mail: sara.maldonado@ehu.eus  20 
ORCID identifiers: 21 
IGA-0000-0002-1571-8408  22 
SMM- 0000-0002-2622-5385 23 
AMAB-0000-0002-6563-4325 24 
PC- 0000-0002-2363-2962 25 
 
 
2 
 
 26 
Acknowledgments. Our special thanks to G. Rodrigo Aispuru, the medical doctor who has 27 
taken part in this project with medical assessment. Also thanks to Exercycle S.L. (BH Fitness 28 
Company) for the machines donated to conduct the exercise intervention. Last but not least 29 
to all undergraduate students who collaborated in this project (2011-2017 academic years).  30 
 31 
  32 
 
 
3 
 
Abstract 33 
Aims To evaluate the influence of diet and aerobic exercise program intervention on cardiovascular 34 
risk (CVR) factors and predicted CVR and vascular age (VA) profiles in overweight/obese people with 35 
primary hypertension (HTN), and to analyze the potential sex differences in the ability to predict VA 36 
and CVR via different methods. 37 
Methods The CVR and VA determined (n=167, 53.7±7.8 yr) using the Framingham Risk Score (FRS) 38 
and the new equation for the prediction of 10-year atherosclerotic cardiovascular disease (ASCVD) 39 
risk, before and after the 16-week intervention period (different aerobic exercise 40 
programs+hypocaloric diet). The sex-specific risk factors considered were age, high-density 41 
lipoprotein cholesterol (HDL-C), total cholesterol, systolic blood pressure (SBP), diabetes mellitus 42 
(DM) and smoking status. 43 
Results From baseline to follow-up, participants reduced (p≤0.001) FRS-CVR score and VA, and SBP. 44 
Total cholesterol decreased significantly, but specifically in men (p≤0.001), and antihypertensive 45 
medication (%) in women (p=0.047). No significant differences over time were observed for HDL-C, 46 
smoking, DM overall for either sex. For ASCVD-CVR there was no overall change or for either sex. 47 
After the intervention, women had a lower CVR score than men (p≤0.001), irrespective of the 48 
calculation method. 49 
Conclusions The improvement in CVR factors after 16-week lifestyle changes reduced the risk of 50 
suffering a cardiovascular event in overweight/obese adults with HTN through the FRS estimation 51 
tool, but not with the ASCVD score. The risk score algorithms could underestimate CVR in women. In 52 
contrast, VA could be a useful and easier tool in the management of individuals with CVR factors. 53 
Keywords: Lifestyle intervention; sex; systolic blood pressure 54 
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1 Introduction 56 
Cardiovascular disease (CVD) is a non-communicable disease, which represents the main cause of 57 
disability and death in the world, including Europe [1, 2]. Globally, between 2006 and 2016 deaths 58 
from CVD increased by 14.5%, although the age-standardized death rate decreased [3]. These data 59 
suggest that this condition needs to receive greater priority in prevention policy to reduce avoidable 60 
risk factors [2, 3]. Prevention is effective, and so, healthy lifestyle behavior promotion in the general 61 
population should directly target unhealthy lifestyles, such as poor-quality diet, physical inactivity, 62 
and smoking, at the individual level [2]. Cardiovascular risk (CVR) factors assessment is the first step 63 
guiding therapeutic strategy for the prevention of CVD [2], and strategy effectiveness depends on 64 
each patient’s CVR profile and predictive risk [4]. 65 
There are several risk factor assessment tools for estimating a patient’s 10-year risk of 66 
developing CVD [2, 4]. However, the most well-established risk score algorithm is the Framingham 67 
Risk Score (FRS), which was initially validated in 1998 to predict CVR [5, 6] and subsequently revised 68 
[7]. Recently, the American College of Cardiology and the American Heart Association developed a 69 
new equation for the prediction of 10-year atherosclerotic cardiovascular disease (ASCVD) risk, the 70 
called “Pooled Cohort Risk Equations” [8, 9]. This new tool was aimed at providing sex- and race-71 
specific estimation of the 10-year risk of ASCVD for African-American and non-Hispanic white men 72 
and women aged 40 to 70 years old [8, 9]. On the other hand, vascular age (VA, i.e., the age of the 73 
vascular system of a person with different CVR factors, calculated as the age a person would be with 74 
the same calculated CVR but whose risk factors were all within normal ranges [10]) is an easily 75 
understood concept related to CVR and calculated according to the definition of D’Agostino from 76 
FRS [7]. 77 
The common prediction factors for CVR models that have a relationship with cardiovascular 78 
events and premature death are age, sex, total cholesterol, high-density lipoprotein cholesterol 79 
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(HDL-C), systolic blood pressure (SBP, including treated or untreated status), diabetes mellitus (DM), 80 
and current smoking status [8]. 81 
Many observational studies have demonstrated graded associations between primary 82 
hypertension (HTN) and increased CVD risk [11] Additionally, adults with HTN usually present other 83 
modifiable CVR factors such as obesity, hypercholesterolemia, DM, smoking, physical inactivity, and 84 
unhealthy diet [12]. Therefore, correcting the dietary habits, lack of exercise and excessive 85 
consumption of alcohol through nonpharmacological interventions alone or in combination with 86 
pharmacological therapy is fundamental for the management of HTN [12]. 87 
A previous study evaluating CVR using the “Pooled Cohort Equations” (sex-specific risk 88 
prediction model) and VA in overweight/obese people with HTN found that CVR was significantly 89 
higher in men than in women despite them having the same CVR values, whereas no differences 90 
were found between sexes in VA [13]. As such, women could have an underestimated CVR profile 91 
based on the misperception that women are “protected” against CVD [14]. Hence, one of the biggest 92 
criticisms of the prediction scales of CVR accuracy is their capacity to overestimate or underestimate 93 
the risk [15]. Currently, there is no known research that measures the effects of an aerobic exercise 94 
program with nutritional intervention on CVR and VA in sedentary and overweight/obese adults with 95 
HTN. Considering the importance of CVR assessment, the objectives of this study were: 1) to 96 
evaluate the influence of 16-week diet and different aerobic exercise programs intervention on CVR 97 
factors and predicted CVR and VA profiles in sedentary and overweight/obese people with HTN, and 98 
2) to analyse the potential sex differences in the ability to predict VA and CVR via different methods 99 
resulting from changes in lifestyle. 100 
2 Methods 101 
The EXERDIET-HTA study was a multi-arm parallel, a randomized, single-blind controlled 102 
experimental trial comparing the effects of 16 weeks of different aerobic exercise programs two 103 
days per week, and dietary intervention in a hypertensive, overweight/obese and non-physically 104 
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active population (www.clinicaltrials.gov, NCT02283047) [16, 17]. The design, selection criteria, and 105 
procedures for the EXERDIET-HTA study have been previously detailed [16]. The study protocol was 106 
approved by the Ethics Committee of The University of the Basque Country (UPV/EHU, 107 
CEISH/279/2014) and the Ethics Committee of Clinical Investigation of Araba University Hospital 108 
(2015-030), and all participants provided written informed consent prior to any data collection. All 109 
follow-up examinations were performed in the same laboratory setting and by the same researchers 110 
as the baseline measurements. Medical staff was blinded to participant randomization.  111 
One hundred and sixty-seven non-Hispanic white participants (n=108 men and n=59 women) 112 
with stage 1 or 2 HTN [≥140 SBP and ≥90 diastolic blood pressure (DBP)] and/or under 113 
antihypertensive pharmacological treatment [16, 18, 19], and classified as overweight (body mass 114 
index (BMI) ≥25 kg/m2 or obese (BMI ≥30 kg/m2) [20]. Participants were recruited from cardiology 115 
services and via local media and were enrolled in the study in Vitoria-Gasteiz (Basque Country, 116 
Spain). 117 
The measurements for CVR factors used in the present study to determine the CVR and VA of 118 
participants were taken before (T0) and after (T1) the 16-week intervention period and were defined 119 
as follows: 120 
Ambulatory blood pressure monitoring was conducted over a 24 hour period using an 121 
oscillometric ABPM 6100 recorder (Welch Allyn, New York, USA) to evaluate SBP (as used to 122 
determine CVR) [8]. The device was used in line with the recommendations set by the European 123 
Society of Hypertension and the European Society of Cardiology guidelines. As such, BP was 124 
measured at 30-minute intervals during awake-time and at 60-minute intervals during the sleep 125 
period. Data were only used if at least 75% of the awake-time and sleep periods were successfully 126 
recorded [16, 18]. 127 
Fasting venous blood (12.5mL) was collected from each participant following an overnight 128 
fast. Diabetes mellitus was defined as fasting glucose of ≥126 mg/dL [21] and/or under 129 
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pharmacological glycemic control treatment. Additionally, measurements of glucose and lipid profile 130 
(total-, and HDL-C) were assayed (ABBOTT, Architect c16000, Orlando, FL, USA). The intra- and inter-131 
assay coefficients of variation were: for glucose 0.65% and 0.84%; for total cholesterol 0.6% and 132 
0.8%; and for HDL-C 1.7% and 1.1%, respectively. 133 
Age and cigarette smoking status were assessed by self-report. All medicines being taken were 134 
ascertained from the participant’s physician. 135 
Cardiovascular risk and vascular age parameters’ assessment have been previously analyzed 136 
in the sample at baseline, and the same procedures were applied for the follow-up study [13]. 137 
Briefly, the Framingham Heart Study assesses the absolute risk to the individual with a percentage 138 
score (i.e., 10% means that there is a 10% chance of having a cardiovascular event within the next 10 139 
years, <6%=low risk; 6-20%=medium risk, and ≥20%=high risk) [7]. The Pooled Cohort Risk Equations 140 
to estimate the 10-year risk was described as a series of steps [8]. The Framingham method was 141 
used to determine the VA of all participants [7], which indicates the biological age of the individual’s 142 
vascular system, as the age a person would be with the same calculated CVR, but whose risk factors 143 
were all within normal ranges. The sex-specific risk factors considered were age, HDL-C, total 144 
cholesterol, SBP, DM, and smoking status. Each variable received a weighted score; the sum of the 145 
score for each variable was then translated into the risk of a CV event in 10 years and VA [7]. 146 
After baseline data collection, participants were randomly allocated to one of the four 147 
intervention groups stratified by sex, SBP, BMI and age using a time-blocked computerized 148 
randomization program by the principal investigator and blind to medical staff. Detailed descriptions 149 
of the exercise and diet intervention procedures have been already reported [16, 17]. Briefly, the 150 
intervention groups were: 1) Attention Control group with physical activity recommendations (i.e., at 151 
least 30 min of moderate-intensity aerobic exercise 5-7 days per week and some dynamic resistance 152 
exercises); and three supervised aerobic exercise groups training two nonconsecutive days under 153 
supervision by exercise specialists, 2) high-volume moderate-intensity continuous training group, 45 154 
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min at moderate intensity; 3) high-volume high-intensity interval training group, 45 min alternating 155 
with different protocols moderate-to-high intensity; and 4) low-volume high-intensity interval 156 
training group, 20 min alternating with different protocols moderate-to-high intensity. All 157 
participants received treatment with a hypocaloric “Dietary Approaches to Stop Hypertension” 158 
(DASH) diet. The diet was designed to provide 25% less energy than their daily energy expenditure 159 
and to achieve a weekly loss of body mass between 0.5 and 1.0 kg. Approximately 30% of their 160 
energy intake came from fat, 15% from protein, and 55% from carbohydrates and was designed in 161 
accordance with the DASH diet [22]. This diet is rich in plant foods (i.e., a rich source of polyphenols) 162 
due to its favourable effect of BP [23]. Every two weeks, participants were weighed and received 163 
encouragement and advice alongside nutritional counseling to aid adherence. 164 
Descriptive statistics were calculated for all variables. Data are expressed as means±standard 165 
deviations (SD) and the range. ANOVA was used to determine if there were significant pre-166 
intervention differences between sexes for the variables: age, BMI, SBP, total cholesterol, HDL-C, 167 
antihypertensive medication, cigarette smoking, DM, CVR, and VA. The comparison of frequencies 168 
between sexes was performed using a Chi-Square test. Repeated measures within-between 169 
participants ANOVAs were used to determine whether there was a significant difference in the 170 
recorded data between pre- and post-intervention for all participants and any time x sex interaction 171 
effects, i.e. to examine whether the change due to the intervention differed between men and 172 
women. A pre- and post-intervention mean difference for each variable was calculated. Statistical 173 
significance was set at P<0.05. All statistical analyses were performed on an intention-to-treat basis 174 
using the SPSS version 22.0. The required sample size was determined for the primary outcome 175 
variable (SBP) and previously published [16, 17]. 176 
3 Results 177 
Baseline characteristics of CVR factors classified by sex are presented in Table 1. The sample was the 178 
same as the previous study [13], but the number of participants is reduced because only those with 179 
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follow-up values were included. The mean age (SD) was 53.7±7.8 years old with 64.7% being men, 180 
12.8% of the participants were smokers, and 9.6% of the sample was suffering from DM. The results 181 
indicated that there were no significant differences between sexes for all CVR factors at baseline, 182 
except for total cholesterol, which was higher in women (mean difference=13.1; 95% CI=25.4-0.85 183 
mg/dL) than in men, with both sexes exceeding cut-off values set by the European Society of 184 
Hypertension and the European Society of Cardiology guidelines [24]. The mean HDL-C was similar in 185 
men and women with both sexes remaining within the healthy cut-off values suggested by the 186 
European Society of Hypertension and the European Society of Cardiology guidelines [24].  187 
The absolute CVR score was significantly different (p<0.001) between sexes with women 188 
having a lower CVR than men, irrespective of calculation method (ASCVD-CVR: mean difference=6.0, 189 
95% CI=4.0-8.0 %, p<0.001; FRS-CVR: mean difference=10.2, 95% CI=7.1-13.4%, p≤0.001, Table 1). 190 
Additionally, in accordance with the ASCVD-CVR score, men were considered to be at medium risk 191 
(10.5%), whereas women were considered to be at low risk (4.5%). However, using the FRS-CVR 192 
score, men were considered to be at high risk (>20%) whereas women were considered to be at 193 
medium risk (11.3%). Consequently, significant differences were found between CVR score 194 
calculators for CVR prediction (p<0.001, mean difference=9.6, 95% CI=10.6-8.6 %). In contrast, there 195 
was no sex difference in VA (mean difference=2.8, 95% CI=-7.5-1.8 yr old, p=0.23), but VA was 196 
significantly higher (p<0.001) than chronological age (CA) (mean difference=17.5, 95% CI=19.4-15.7 197 
yr old), irrespective of sex, (p<0.001). 198 
Table 2 shows CVR factors, CVR scores and VA values at baseline and follow-up. After the 199 
intervention, all participants showed decreased SBP, total cholesterol, antihypertensive medication 200 
usage (%), CVR score predicted by FRS, and VA (p<0.05). ANOVA showed that SBP decreased in both 201 
sexes (T0 vs. T1 difference %, men =7.4 %; women, =6.0 %, p≤0.001). Significant time x sex 202 
interaction effects revealed that mean total cholesterol significantly reduced in men (=13.6 %, 203 
p≤0.001), but not in women (=6.5 %, p=0.12), and antihypertensive medication (%) significantly 204 
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decreased in women (=10.2 %, p=0.047), but not in men (=4.6 %, p=0.30). No significant 205 
differences were observed in HDL-C, smoking habit and suffering from DM after 16-weeks 206 
intervention period. When CVR score and VA were analyzed, FRS-CVR and VA decreased overall, and 207 
in both sexes (FRS-CVR: men =4.0 %; p≤0.001; women, =2.0 %; p=0.01) and (VA: men =5.6 %, 208 
p≤0.001; women, =6.5 %; p≤0.001, Figure 1). However, no significant changes over time were 209 
observed in ASCVD-CVR overall or for either sex (men =0.8 %, p=0.30; women =0.5 %, p=0.08). 210 
Finally, the magnitude of change in each CVR variable due to the intervention was not significantly 211 
different from each other between sexes, despite some single factor reductions being significant 212 
only for men or women, as described above. However, after intervention period, the CVR score 213 
remained significantly different (p<0.001) between sexes (at follow-up) with women having a lower 214 
CVR than men, irrespective of calculation method (ASCVD-CVR: mean sex difference=5.6, 95% 215 
CI=3.0-8.2 %, p<0.001; FRS-CVR: mean sex difference=8.1, 95% CI=5.1-11.2%, p≤0.001, Table 2). 216 
4 Discussion 217 
To our knowledge, this is the first study investigating the impact of a 16-week intervention 218 
(hypocaloric DASH diet plus aerobic exercise) on CVR factors, CVR score calculators and VA in 219 
sedentary overweight/obese and hypertensive adults. The main findings of the study were that after 220 
aerobic exercise and hypocaloric DASH diet intervention: 1) participants significantly improved SBP, 221 
total cholesterol and decreased antihypertensive medication usage; 2) CVR and VA using the FRS 222 
model was significantly reduced in both sexes but not CVR estimated by ASCVD Pooled Cohort 223 
Equations; 3) regardless of the CVR assessment tool, men showed significantly higher values than 224 
women post-intervention albeit no differences in percentage change resulting from the intervention, 225 
and 4) VA could better identify the effect of a non-pharmacological intervention in both sexes than 226 
other CVR tools. 227 
Based on a rigorous approach to the validation of equations, the American College of 228 
Cardiology and the American Heart Association guideline strongly recommends the use of Pooled 229 
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Cohort Equations in non-Hispanic African Americans and non-Hispanic whites (40 to 79 years old) for 230 
the assessment of the 10-year risk of a first hard ASCVD event [8]. However, although the ASCVD-231 
CVR equations have been developed from the FRS [7, 8], and the role of the major variables in the 232 
development of CVR was similar in both score calculators, in the present study, after the exercise 233 
and diet intervention, CVR was still 7.1% lower with ASCVD-CVR than with FRS-CVR (P<0.001) in all 234 
participants (Table 2). Thus, the observed and predicted risks for participants in this study at follow-235 
up were 9.6% and 17.6% (medium risk) in men and 4.0% (low risk) and 9.4% (medium risk) in women 236 
for the ASCVD-CVR and FRS-CVR, respectively. Hence, it could be considered that the ASCVD-CVR 237 
score calculator by the American College of Cardiology and the American Heart Association would 238 
identify the least number of participants with CVR (i.e., underestimation), or the FRS-CVR would 239 
stratify a maximum number of individuals with high CVR (i.e., overestimation) [6]. This difference 240 
could likely be caused by the objective of each score; the FRS estimates CVR for a large combination 241 
of CVD outcomes and the ASCVD tool estimates risk mainly for myocardial infarction (fatal and 242 
nonfatal) and stroke only [25] and does not consider family history, which influences mortality [25].  243 
An appropriate lifestyle change, including diet and exercise, has been shown to effectively 244 
improve markers of CV health [18, 19] and CVD prevention [2]. Likewise, previous studies have 245 
proven that a dose-response curve for physical activity and HTN has a clinically meaningful role in 246 
primary prevention of HTN [26], along with a diet rich in polyphenols [23]. Related to that, in the 247 
current study, the decreases (p<0.05, before-after intervention) in SBP (∆=7.3 mmHg in men and ∆=6 248 
mmHg in women), total cholesterol in men (∆=13.6 mg/dL) and antihypertensive medication use in 249 
women (∆=10.5%) could rightfully be considered the reason underlying the reduction in the FRS-CVR 250 
score and VA. However, given that drug therapy for primary prevention of CVD is nowadays based 251 
on absolute CVD risk, where the BP-lowering drug treatment is determined by BP level along with 252 
other CVR factors (i.e., sex, age, total cholesterol, HDL-C, DM, and smoking status) [27], and that a 253 
reduction of 5 mmHg in SBP was associated with a lower risk of CVD mortality [28], it seems that the 254 
ASCVD-CVR estimation tool does not have enough sensitivity to show the benefits of a lifestyle 255 
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intervention. Hence, the lack of significant changes in ASCVD-CVR estimation, in the presence of 256 
other CVR factor improvements, could have a negative effect on the advice to treat individuals with 257 
an ASCVD-CVR >7.5% with statins [15]. It is important, therefore, to note that treatment decisions 258 
should be individualized (i.e., after a clinician-patient risk/benefit discussion addressing optimal 259 
lifestyle), as suggested by the latest cholesterol guidelines [29], and not just absolute CVR 260 
estimation. 261 
On the other hand, the present study showed that after 16-week of intervention with diet 262 
and aerobic exercise, absolute CVR remained higher in men than in women for both CVR scores 263 
(ASCVD, 5.6%; FRS, 8.2%). As such, the straightforward discussion would claim that men have a 264 
higher risk of suffering a CV event in the following 10 years, underlining the sex differences in life 265 
expectancy and quality of life, due, in part, to unhealthy behaviors [30]. However, a deeper analysis 266 
of data and literature revealed that in the current study after lifestyle intervention: 1) there were no 267 
differences in the percentage change after intervention between men and women (ASCVD, p=0.73; 268 
FRS, p=0.09); 2) post-intervention women showed higher total cholesterol values with 269 
hyperlipidemia >190mg/dL, with no differences in HDL-C (normal values >40 mg/dL), 270 
antihypertensive medication use, smoking habit or DM compared to men; 3) the new cholesterol 271 
guidelines have no sex-specific differences in recommendations [31], and 4) menopausal status in 272 
women is not taken into account when CVR is estimated irrespective of tool (in this study 50% were 273 
post-menopausal women). Given this, and that deaths from CVD have been greater in women 274 
compared with men over the past 30 years, with CVR increases during the menopausal transition 275 
and after menopause mainly marked by progressive endothelial dysfunction [32], would be logical to 276 
conclude that CVR is underestimated in women. 277 
Noting the imprecise previous tools for calculating the CVR, mainly due to the various 278 
underlying mathematical models used to calculate the scores, VA could be a useful tool in the 279 
management of individuals with CVR factors, and easier to use and understand the effect of an 280 
intervention in terms of life years [10]. Thus, in the present study after 16-week lifestyle 281 
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intervention, VA decreased in all participants (Table 2, Figure 1) with no differences between sexes. 282 
These results could identify biologically plausible mechanisms underlying exercise and diet-induced 283 
effects on CVD risk reduction irrespective of sex. Overall, the CVR factors-associated arterial wall 284 
thickening, which contributes to vascular stiffening, are sensitive to a non-pharmacological lifestyle 285 
intervention [33]. 286 
Although the present study has highlighted the importance of determining CVR factors in a 287 
hypertensive population after a lifestyle intervention, several limitations should be acknowledged. 288 
Firstly, although the sample size was sufficient as an initial investigation into CVR and HTN; it would 289 
not be comparable to that of larger epidemiological studies, and future studies should consider 290 
large-scale investigations. Secondly, the current study only had 35.3% of women which does not 291 
represent an equal gender split. As this poses statistical issues, future studies should look to recruit 292 
equal numbers, or even to study effects only in women.  293 
5 Conclusions 294 
The improvements in CVR factors after a 16-week lifestyle change intervention reduced the risk of 295 
suffering a CV event in the following 10 years in overweight/obese adults with HTN assessed with 296 
the FRS estimation tool. However, the ASCVD-CVR score calculator was not sensitive enough to show 297 
the benefits of diet and exercise. The risk score algorithms (FRS and ASCVD) might underestimate 298 
the CVR in women as they always consider men to be higher risk irrespective of age. Therefore, VA 299 
could be a useful tool in the management of individuals with CVR factors, and easier to apply and 300 
understand the effect of an intervention in terms of life expectancy. 301 
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Figure legends 313 
Figure 1. Vascular age (VA) values at baseline (T0) and follow-up (T1) periods compared 314 
to chronological age (CA). 315 
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